🇰🇷 South Korea Country × Condition
neurofibroma plexiform Clinical Trials in South Korea
Active clinical trials for neurofibroma plexiform with research sites in South Korea. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 1 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇰🇷 South Korea
Active Trials in South Korea (2)
NCT06360406
Recruiting
Real-World Treatment Study of Koselugo (Selumetinib)
Enrollment
200 pts
Country
🇰🇷 South Korea
AstraZeneca
View Trial → NCT06961565 Phase 1
Recruiting
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Enrollment
56 pts
Country
🇰🇷 South Korea
Pasithea Therapeutics Corp.
View Trial → Frequently Asked Questions
How many neurofibroma plexiform clinical trials are active in South Korea?
There are currently 2 active clinical trials for neurofibroma plexiform with sites in South Korea, of which 2 are actively recruiting patients.
How can I join a neurofibroma plexiform clinical trial in South Korea?
To join a neurofibroma plexiform clinical trial in South Korea, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in South Korea directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are neurofibroma plexiform trials in South Korea?
Active neurofibroma plexiform trials in South Korea span Phase 1. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology